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UNCERTAINTIES
Which emollients are effective and acceptable for
eczema in children?
Matthew J Ridd GP and reader in primary healthcare 1, Amanda Roberts patient and carer 2, Douglas
Grindlay information specialist 3, Hywel C Williams professor of dermato-epidemiology 3
1Population Health Sciences, University of Bristol, Bristol BS8 2PS, UK; 2Nottingham Eczema Support Group for Carers of Children with Eczema,
Nottingham, UK; 3Centre of Evidence Based Dermatology, University of Nottingham, UK
What you need to know
• Although emollients alone can help reduce the symptoms of eczema
and prevent flares, most people will need to use anti-inflammatory
treatments such as topical corticosteroids of an appropriate strength
and duration as well
• Effectiveness and acceptability of emollients varies according to disease
severity, body site, climate, container, and patient or carer preferences
and beliefs
• Based on current evidence, the “best” emollient is the one that the
individual prefers after a period of testing
Atopic eczema or dermatitis, commonly referred to as eczema,
is characterised by dry, itchy skin. Although mainly a childhood
condition, this disease commonly persists into or develops in
adulthood.1 Patients are advised to use “leave-on” emollients
or moisturisers, applied directly to the skin which add or help
retain moisture.2 3 While evidence of their clinical effectiveness
is limited, their use is ingrained in clinical practice and
guidelines.2
Many different emollients can be prescribed or bought over the
counter. Most are formulated as lotions, creams, gels, or
ointments (see infographic). There is little evidence to
recommend one type of emollient over another. Healthcare
professional recommendation is the main source of advice when
choosing a prescribed emollient.4 Preferences of the patient or
carer are critical and may be influenced by the characteristics
of the emollient, patient, and environment.5 The National
Institute for Health and Care Excellence (NICE) recommends
patients try different emollients in the clinic before choosing.2
This approach is not practical in most primary care settings, and
even in specialist clinics the range of emollients available to try
can be arbitrary and influenced by pharmaceutical companies
and local formularies.
Older, cheaper emollients may be as effective as newer, more
expensive ones,6 and the advantages of products that claim
“dermatologically tested,” “fragrance-free,” and
“hypoallergenic” are dubious.7 Through a process of trial and
error, families often try many different emollients before either
finding one that works for them8 9 or giving up and turning to
unorthodox treatments which may be harmful.10
“Which emollients are the most effective and safe in treating
eczema?” emerged as one of the highest ranked uncertainties
in a James Lind Alliance research priority setting exercise
involving patients and healthcare professionals.11
What is the evidence of uncertainty?
Sources and selection criteria
A Cochrane review published in 2017 evaluated the effectiveness of emollients
in eczema. To supplement the Cochrane Review, we searched Ovid MEDLINE,
and Embase for studies between 2017 and 2019 comparing different leave-on
emollients for children with eczema. We used variations of terms such as
infant, baby, child, adolescent, paediatrics, emollients, and eczema.
A Cochrane Review (77 trials, 6603 participants) noted
beneficial effects with use of most emollients for eczema in
prolonging time to flare, reducing the number of flares and the
need for topical corticosteroids. The evidence on whether some
moisturisers or their ingredients were better than others is
inconclusive,12 leading to uncertainty about how emollients
compare, both across and within each type. Most studies (70/77)
had “unclear” to “high” risk of bias. Most head-to-head
comparisons had been evaluated in single studies which
generally had small sample sizes. Participant‐assessed disease
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severity was reported in 24 studies, and three studies used a
validated instrument. Participant satisfaction with treatment was
assessed in 13 studies. Reporting of adverse events—commonly
rash, itch. pain, or stinging—with use of emollients was limited.
Subsequently, the COMET study reported on the feasibility of
a trial in primary care comparing four different types of
emollients (Aveeno lotion, Diprobase cream, Doublebase gel,
Hydromol ointment) in children up to 5 years of age.13 It was
not powered to compare the effectiveness of the interventions,
but eczema severity improved in all groups over a 12 week
period.14 An open-label study15 16 randomised 335 children aged
2-6 years with mild to moderate atopic dermatitis to Dexeryl
(V0034CR) cream, Atopiclair cream, or no emollient: the
proportion of patients with one or more flares and the number
of flares was lower in both emollient groups, with Dexeryl cream
seeming to perform better than Atopiclair cream.
This uncertainty is reflected in prescribing guidance. A recent
review in England and Wales identified 102 different emollient
formularies that made conflicting recommendations about 109
different emollients.17
Is ongoing research likely to provide
relevant evidence?
Because of variability of eczema and associated skin dryness
between and within patients, it is unlikely that any one emollient
will suit everyone. Further evidence must guide “first line”
emollient recommendations based on comparative clinical
effectiveness and safety in children.
We are running a trial comparing different leave-on emollients
in children with eczema. The BEE (best emollients for eczema)
study is recruiting children aged 6 months to 12 years in
England, and will report in 2021 (www.isrctn.com/
ISRCTN84540529, www.bristol.ac.uk/bee-study). The study
compares four of the most commonly prescribed types of
paraffin-based emollient: lotions, creams, gels, and ointments.
The primary outcome is a patient-reported measure of eczema
symptoms (POEM) over 16 weeks, with eczema signs and
quality of life as secondary outcomes. Participants will be
followed up for 52 weeks, and a nested qualitative study will
explore perceived effectiveness and acceptability of study
emollients by carers and older children.
We searched Cochrane CENTRAL and WHO ICTRP databases
(using the terms emollient OR emollients OR moisturiser OR
moisturisers OR moisturizer OR moisturizers) and found no
other ongoing trials in children.
Recommendations for future research
• What are the characteristics of an “ideal” emollient and how do people
trade-off different aspects such as frequency of application and
consistency?
• What is the optimum quantity or frequency of application and how does
this vary by eczema severity and type of emollient?
• Are “brand” and “generic” emollients equivalent in their effectiveness,
acceptability, and adverse effects?
• Are new emollients any better than old?
What should we do in the light of the
uncertainty?
Discuss the uncertainty with your patient
Promote an open and honest conversation about what emollients
are for, what patients have bought or had prescribed before,
how often they were applied, and what they did or did not like
about them. Consider factors that may affect clinician and
carer/patient preference for different emollients (see
infographic). Ensure carers and older children understand that:
•There are four main formulation types, and we do not know
whether one emollient is better than another
•There may be trade-off between effectiveness and
acceptability—the best emollient(s) for them may change
over time and vary by body site, by whether the eczema is
acute or chronic, and by season, but will be one(s) that they
are willing to use regularly
•An ointment is greasier, can be hard to apply, and is less
cosmetically acceptable. It may be preferred in more severe
eczema over a cream, for example, because it requires less
frequent application and does not contain any additives
that may irritate the skin
•Some are more acceptable as “soap substitutes” than others.
Prescribing an emollient
Refer to your local formulary and start with emollients without
urea or antimicrobials. These ingredients are more likely to
cause irritation and are generally reserved for troublesome or
recurrently “infected” eczema.5 Some problems with emollients
can be related to specific ingredients, such as sodium lauryl
sulphate (SLS). Avoid prescribing an alternative with the same
skin “sensitisers.” MIMS provides one readily accessible source
to help guide clinicians.18 Aqueous cream is not recommended
as a leave-on treatment.12 Prescribing one or more emollients
in 100 g quantities as “testers,” to try on different body sites
may be preferred initially. Make appropriate amounts (500 g or
mL) of the preferred emollient(s) available on repeat
prescription, allowing for supplies for nursery or school.
Topical corticosteroids will be needed by children with all but
the mildest eczema to treat or, used prophylactically,19 to prevent
disease flares. Ensure that the family have an adequate supply
and confidence to use them according to the site and severity
of eczema. A common reason for discontinuation of emollients
is “stinging,” which may be due to under-treated inflamed skin
and will only improve with topical corticosteroids (or calcineurin
inhibitors where there are concerns about the site or duration
of use).
Explain how it is to be used
Explain how best to apply the emollient: with clean hands, using
downward strokes (to reduce the risk of folliculitis), allowing
it to soak in (rather than rubbing). Emollients that come in pots
can act as a potential infection reservoir. To reduce this risk,
spoon the emollient out when needed and replace the lid.
Be specific on frequency of application (usually at least twice
daily and as required) and timing in relation to topical
corticosteroids (allowing up to 60 minutes between the
applications to avoid dilution, order probably doesn’t matter).
Direct patients to reliable sources of written information and
consider giving them a personalised treatment plan.20
Follow-up
Offer review in two to four weeks (by telephone if suitable and
preferable for the carer) to reassess disease severity, treatment
use, and the acceptability of the emollient(s) to the family. Offer
alternatives according to any reported problems, such as a
thinner emollient where cosmesis is a concern. Finding a safe
and acceptable regimen that achieves the outcome(s) important
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to the family is more important than focusing on frequency or
quantity of emollient use.
Patients’ perspective
“Many of our member families tell us how important the texture, smell, or
sensation of creams are to their children. Without the young patients' buy-in,
treating eczema can turn into discouraging daily battles for parents and carers.
Reducing choice or access to a variety of eczema treatments is a is a huge
risk as they may not ‘work’ as well, or adherence to treatment may decrease,
leading to the deterioration of the skin condition and triggering return GP
appointments or referrals to secondary care.”
Magali Redding, chief executive officer of Eczema Outreach Support (a charity
providing practical and emotional support to families of children and young
people with eczema in the UK, www.eos.org.uk)
What patients and carers need to know
• Eczema is an inflammatory skin disease that needs anti-inflammatory
treatment with topical corticosteroids to get redness and itching under
control
• Emollients treat the dry skin associated with eczema and may help to
prevent flares
• Research comparing different “leave-on” emollients is limited, so the
key thing is to find one(s) that suits you and your child, which over time
may change
• It is important to apply emollients to your child regularly (usually twice
a day) as a maintenance treatment
• Emollients are safe, and any adverse effects are usually localised and
mild. However, take care to avoid any slips or falls through their use,
such as when washing
• Do not smoke or go near naked flames because clothing or fabric that





• How do you routinely discuss the different types of emollients available
with patients when prescribing?
• Review whether patients with eczema you have seen at your practice
have been prescribed an anti-inflammatory treatment alongside their
emollient
• How do you review the use and acceptability of eczema treatments by
carers and patients?
How patients were involved in the creation of this article
Our discussions with parents of children with eczema who are members of
the BEE study’s Patient and Public Involvement group informed the initial
draft. One of our coauthors has had eczema all her life and has raised two
children with eczema. Issues raised and incorporated into the article were:
problematic use of terms such as “hypoallergenic”; the variability of eczema
between and within people, meaning there is unlikely to be any “best” emollient;
concerns about restriction of access to different emollients and carer/patient
choice; the importance of emollients being provided for use at nursery or
school, the possible need for different types for different body sites, purposes,
and over time; sensory aspects of emollients; and the potential versatility of
one emollient as both leave-on emollient and soap substitute.
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